UCL Mont-Godinne

Yvoir 17 trials 5 recruiting

17 Registered trials

5 Currently recruiting

Organisation

UCL Mont-Godinne

Location

Yvoir, Belgium

Identifier

ORG-100031659

Address

Avenue Dr-Gaston-Therasse 1, 5530, Belgium

Departments

Cardiology
Department of Oncology
Haematology
Haematology Department
Hematology
N/A
Oncology
Oncology Department
Pneumologie
Pneumologie Route 27
Pneumology department
Rheumatology
Soins Intensifs

Clinical trials at this site (17)

Search interface

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting

2023-507031-38-00 Severe viral lung infections 5 2023-01-09
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 idiopathic pulmonary fibrosis (IPF) 5 2024-09-10
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting

2023-505028-74-00 Coronary artery disease 5 2024-01-29
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting

2022-501181-22-01 Pancreatic adenocarcinoma 4 2023-02-06
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended

2023-503384-41-00 Relapsed or refractory diffuse large B-cell lymphoma (D 5 2020-12-22
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i… Ended

2023-506033-29-00 EGFR Exon 20ins Mutated Locally Advanced or Metastatic 5 2020-10-09
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended

2022-501505-13-00 Metastatic melanoma 1 2023-03-31
A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C… Ended

2022-502031-20-00 Non-squamous non-small cell lung cancer (NSCLC) 10 2020-12-17
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12
RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended

2023-510189-28-00 Rheumatoid Arthritis 6 2018-05-15
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended

2023-509472-42-00 Relapsed and/or Refractory Multiple Myeloma 5